GSK plc (LON:GSK – Get Free Report) has been assigned a consensus recommendation of “Hold” from the eight research firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating on the company. The average twelve-month price target among analysts that have covered the stock in the last year is GBX 2,145.
A number of brokerages recently weighed in on GSK. Royal Bank Of Canada started coverage on shares of GSK in a report on Tuesday, September 8th. They set a “sector perform” rating and a GBX 1,975 price objective for the company. Berenberg Bank reaffirmed a “buy” rating and issued a GBX 2,200 price objective on shares of GSK in a research report on Tuesday, November 3rd. Jefferies Financial Group restated a “buy” rating and set a GBX 2,500 target price on shares of GSK in a research report on Tuesday, October 20th. Finally, Deutsche Bank restated a “hold” rating and set a GBX 2,000 price target on shares of GSK in a research report on Tuesday, November 10th.
Get Our Latest Stock Analysis on GSK
GSK Price Performance
LON GSK opened at GBX 1,851.50 on Thursday. The company has a market capitalization of £74.23 billion, a PE ratio of 17.32, a price-to-earnings-growth ratio of 1.24 and a beta of 0.28. GSK has a fifty-two week low of GBX 1,690 and a fifty-two week high of GBX 2,282. The business’s fifty day moving average is GBX 1,850.76 and its 200 day moving average is GBX 1,952.50. The company has a debt-to-equity ratio of 126.38, a quick ratio of 0.73 and a current ratio of 0.86.
GSK (LON:GSK – Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The company reported GBX 54.60 earnings per share (EPS) for the quarter. GSK had a net margin of 12.97% and a return on equity of 24.64%. The business had revenue of GBX 888.70 billion during the quarter. Sell-side analysts predict that GSK will post 175.98 earnings per share for the current year.
Insider Activity at GSK
In other news, insider Anne Beal purchased 637 shares of GSK stock in a transaction dated Friday, September 18th. The shares were purchased at an average price of GBX 4,985 per share, with a total value of £31,754.45. Also, insider Jonathan Symonds acquired 1,500 shares of the business’s stock in a transaction that occurred on Friday, September 18th. The stock was purchased at an average price of GBX 1,881 per share, for a total transaction of £28,215. In the last three months, insiders bought 2,151 shares of company stock valued at $6,021,921. Corporate insiders own 0.20% of the company’s stock.
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.
Recommended Stories
- Five stocks we like better than GSK
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
